Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyperbaric lidocaine is an intrathecal **5% lidocaine hydrochloride and 7.5% dextrose** sterile solution used to induce spinal anesthesia. Lidocaine is an amide local anesthetic that reversibly blocks voltage-gated sodium channels in neuronal membranes, preventing action-potential initiation and propagation and thereby producing sensory, motor, and autonomic blockade. Dextrose makes the solution hyperbaric relative to cerebrospinal fluid, allowing anesthetic spread to be influenced by patient positioning. The labeled formulation contains 50 mg/mL lidocaine hydrochloride and 75 mg/mL dextrose and is indicated for spinal anesthesia; it has also been studied in a randomized trial for adults undergoing cystoscopy. ([labeling.pfizer.com](https://labeling.pfizer.com/ShowLabeling.aspx?id=5361))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyperbaric lidocaine (Hospira, Inc.).